Scientists found a promising new method for detecting and treating the recurrence of ovarian cancer -
Researchers from the Mayo Clinic Center for Individualized Medicine have found a new way promising to monitor and treat ovarian cancer recurrence - a difficult disease to detect that claims many lives. A new study from George Vasmatzis, Ph.D., of the Department of Laboratory Medicine and Pathology at the Mayo Clinic, include liquid biopsies from blood tests and DNA sequencing can detect cancer return of ovary long before a tumor reappears. This could lead to early intervention and more effective treatment, individualized. Dr Vasmatzis's research on the "Quantification of Somatic chromosome rearrangements in Circulating free DNA Cell-De ovarian cancer" is published in the July 20 Scientific Reports .
"With liquid biopsies, we should not expect that the growth of the tumor to obtain a DNA sample," explains Dr. Vasmatzis. "This important discovery makes it possible for we detect disease recurrence earlier than other diagnostic methods. We can repeat the liquid biopsies to monitor the progression of cancer. This gives hope for a better treatment plan over time. "
The study was performed on 10 patients with advanced ovarian cancer. Blood was drawn before and after . surgery investigators compared the DNA of liquid blood biopsies DNA tissue samples of the tumor, using mate-pair sequencing. - A exome sequencing all inexpensive that can reveal genetic changes that contribute to tumor growth
"in this study, blood taken prior to and after surgery, and surgical tissue was used to identify DNA fragments with abnormal junctions that can not be seen in the DNA tumor of this patient, "says Dr. Vasmatzis." the next-generation sequencing companion pair was used to identify specific DNA changes in the tumor to create an individualized follow-up group for a liquid biopsy. This allows us to tailor treatment for each patient rather than using a standard treatment may not work for everyone. "
When post-surgery DNA matched that of the tumor, patients were later found to have had a recurrence of ovarian cancer. However, when the post-operative DNA did not match the DNA of the tumor, patients were found to be in remission.
EmoticonEmoticon